Show simple item record

dc.contributor.authorStavrinides, V
dc.contributor.authorParker, CC
dc.contributor.authorMoore, CM
dc.date.accessioned2017-07-13T13:09:48Z
dc.date.issued2017-07
dc.identifier.citationCancer treatment reviews, 2017, 58 pp. 14 - 21
dc.identifier.issn0305-7372
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/691
dc.identifier.eissn1532-1967
dc.identifier.doi10.1016/j.ctrv.2017.05.004
dc.description.abstractAlthough the incidence of prostate cancer is rising due to PSA screening and increased life expectancy, the metastatic potential of low-grade, organ-confined disease remains low. An increasing number of studies suggest that radical treatment in such cases confers little or no survival benefit at a significant cost to morbidity. Active surveillance is a promising management approach of such low-risk cancers: eligible patients are selected based on clinical and pathological findings at diagnosis and are regularly monitored with digital rectal examinations, PSA testing and biopsies. Treatment, however, is deferred until and unless there is evidence of disease progression. This is a key difference from watchful waiting, where treatment is avoided until and unless there are symptoms. The purpose of this work is to review the rationale and evidence behind active surveillance and to offer an overview of current active surveillance strategies and outcomes.
dc.formatPrint-Electronic
dc.format.extent14 - 21
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectProstate-Specific Antigen
dc.subjectMagnetic Resonance Imaging
dc.subjectRisk Factors
dc.subjectMale
dc.subjectDigital Rectal Examination
dc.subjectWatchful Waiting
dc.titleWhen no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers.
dc.typeJournal Article
dcterms.dateAccepted2017-05-16
rioxxterms.versionofrecord10.1016/j.ctrv.2017.05.004
rioxxterms.licenseref.startdate2017-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer treatment reviews
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume58
pubs.embargo.termsNot known
dc.contributor.icrauthorParker, Chrisen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record